Clinical development of CT-P6 in HER2 positive breast cancer

References

• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
   PubMed Web of Science ®Google Scholar
• Noone AM, Cronin KA, Altekruse SF, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992–2013. Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):632–641.
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39–51.
   PubMed Web of Science ®Google Scholar
• Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene. 2007 Oct 11;26(46):6577–6592.
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744–3752.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017 Mar 25;389(10075):1195–1205.
   PubMed Web of Science ®Google Scholar
• Fornier M, Esteva FJ, Seidman AD. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol. 2000 Dec;27(6):38–45.
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene. 2007 May 28;26(25):3637–3643.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Apr 1;20(7):1800–1808.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant Trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273–1283.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO model list of essential medicines, 20th list (‎March 2017, amended August 2017)‎. World Health Organization; 2017; [cited 2019 Sep 6]. Available from: https://apps.who.int/iris/handle/10665/273826.
   Google Scholar
• Mayor S. WHO includes 16 new cancer drugs on list of essential medicines. Lancet Oncol. 2015 Jul;16(7):757.
   PubMed Web of Science ®Google Scholar
• Kent DRS, Di Biase S. Disruption and maturity: the next phase of biologics. Quintile IMS, 2017.
   Google Scholar
• Stebbing J, Baranau Y, Manikhas A, et al. Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer. Expert Rev Anticanc. 2018;18(6):531–541.
   PubMed Web of Science ®Google Scholar
• Roche. Annual investor report. F. Hoffman-La Roche Ltd; 2018; [cited 2019 Sep 6]. Available from: https://www.roche.com/dam/jcr:af865dfd-50fb-458b-9cac-34097db9d3ec/en/ar18e.pdf
   Google Scholar
• Fleck LM. The costs of caring: who pays? Who profits? Who panders? Hastings Cent Rep. 2006 May -Jun;36(3):13–17.
   PubMed Web of Science ®Google Scholar
• Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol. 2012 Mar;7:S57–S67.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2018 Nov -Dec;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Blackwell K, Gligorov J, Jacobs I, et al. The global need for a trastuzumab biosimilar for patients with HER2-positive breast cancer. Clin Breast Cancer. 2018 Apr;18(2):95–113.
   PubMed Web of Science ®Google Scholar
• FDA US. Biologics price competition and innovation act 2009. [cited 2019 Sep 6]. Available from: fda: gov/downloads/drugs/guidancecomplianceregulatoryinformation/ucm216146.pdf
   Google Scholar
• Jeong SA, Choi JM, Park JM, et al. Mechanism of action of the trastuzumab biosimilar CT-P6. Expert Opin Biol Ther. 2018;13:1–11.
   Web of Science ®Google Scholar
• Leveque D, Gigou L, Bergerat JP. Clinical pharmacology of trastuzumab. Curr Clin Pharmacol. 2008 Jan;3(1):51–55.
   PubMedGoogle Scholar
• Esteva FJ, Stebbing J, Wood-Horrall RN, et al. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Cancer Chemoth Pharm. 2018 Mar;81(3):505–514.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Saeki T, Kim H, et al. Efficacy and safety of the trastuzumab biosimilar candidate CT-P6. Future Oncol. 2018 Aug;14(19):1909–1919.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Yu S, Kim M, et al. Pharmacokinetics of CT-P6 and reference trastuzumab by clinical factors in patients with HER2 positive early-stage breast cancer (EBC). J Clin Oncol. 2018 May 20;36:15.
   Web of Science ®Google Scholar
• Keizer RJ, Huitema ADR, Schellens JHM, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507.
   PubMed Web of Science ®Google Scholar
• Trastuzumab package insert. In: FDA US, editor. 2010. [cited 2019 Sep 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf
   Google Scholar
• Celltrion Healthcare HERZUMA® (trastuzumab-pkrb) [package insert]. Revised 2018 Dec; cited 2019 Aug 27. Available from: https://wwwaccessdatafdagov/drugsatfda_docs/label/2018/761091s000lblpdf
   Google Scholar
• Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017;18(7):917–928.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Lee SJ, Stebbing J, et al. Phase I clinical trial comparing PK and safety of trastuzumab and its biosimilar candidate CT-P6. Breast. 2017;32:S68–S69.
   Web of Science ®Google Scholar
• Im Y, Krasnozhon D, Bondarenko I, et al. Phase I/Iib Clinical Trial Comparing Pk and Safety of Trastuzumab and Its Biosimilar Candidate Ct-P6. Breast. 2013;22:S108–S108.
   Web of Science ®Google Scholar
• Esteva FJ, Baranau Y, Baryash V, et al. Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC). Ann Oncol. 2017 Sep;28 (suppl 5): 43-67.
   Google Scholar
• Esteva FJ, Chung HC, Royce ME, et al. Cardiotoxicity in 1 year of treatment with reference trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early stage breast cancer (EBC) patients. Cancer Res. 2018;78:4.
   Web of Science ®Google Scholar
• Lee J, Kang HA, Bae JS, et al. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. Mabs-Austin. 2018;10(4):547–571.
   PubMed Web of Science ®Google Scholar
• Jeon CW, Choi JH, Jung SU, et al. Clinical experience of CT-P6 for HER2 positive breast cancer: a case series. Breast. 2019;44:S21–S21.
   Web of Science ®Google Scholar
• P W. NHS saved £324 million by switching to biosimilars and generics. Pharmaphorum2018. p. pharmaphorum.com/news/nhs-saved-millions-switching-biosimilars/.
   Google Scholar
• HER2-positive Breast Cancer ESMO 2018. Use of trastuzumab biosimilar CT-P6 enables high cost savings. Breast Care. 2018;13(6):463.
   Web of Science ®Google Scholar
• Suh D, Lee S, Suh D. Budget impact of substituting biosimilar Trastuzumab (Ct-P6) in treating gastric cancer and breast cancer in 28 European Countries. Value Health. 2018 Oct;21:S25–S25.
   Web of Science ®Google Scholar